PRIMOLUT DEPOT INJECTION

Indications

• Metabolic disorders
• Food additive
• Potential role in cannabinoid synthesis

Dosage

Children: Refer to the BNF for Children for appropriate dosing information.

Adults: Refer to specific clinical guidelines or consult the BNF for appropriate dosing information.

Mechanism of action

Caproate acts as a precursor in the cannabinoid biosynthesis pathway. It influences lipid metabolism and may modulate various physiological processes through its interaction with fatty acid receptors, although specific receptor interactions and downstream effects require further elucidation.

Pharmacodynamics

Caproate is associated with lipid metabolism and may have roles in energy production and cellular signaling. Its effects can vary based on concentration and biological context, contributing to metabolic processes and potentially impacting appetite regulation and energy homeostasis.

Pharmacokinetics

Caproate is absorbed through the gastrointestinal tract and metabolized in the liver. It undergoes β-oxidation to produce energy and can be incorporated into various lipid structures. The pharmacokinetic profile, including absorption, distribution, metabolism, and excretion, can be influenced by factors such as diet and individual metabolic rates.

Pregnancy

There is limited data on the use of caproate in pregnancy. Caution is advised.

Breast-feeding

Caution is advised as the effects on the nursing infant are not well studied.

Storage

Store in a well-closed container at room temperature, away from light.

Indications

• Amenorrhea
• Endometrial hyperplasia
• Hormone replacement therapy
• Prevention of preterm birth in at-risk pregnancies

Dosage

Children: Refer to the BNF for Children for appropriate dosing recommendations.

Adults: Refer to the BNF for specific dosing guidelines based on the indication.

Mechanism of action

Hydroxyprogesterone functions primarily by acting as an antigonadotrophic agent on the anterior pituitary, inhibiting the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This inhibition leads to decreased follicular growth and estrogen production, ultimately preventing ovulation and the formation of corpora lutea. The sustained action of progesterone helps maintain hormonal balance, particularly during the luteal phase of the menstrual cycle.

Pharmacodynamics

As a progestin, hydroxyprogesterone exhibits various pharmacodynamic effects including the regulation of menstrual cycles, modulation of uterine lining, and maintenance of pregnancy. Its ability to inhibit LH and FSH results in reduced ovarian activity, which is beneficial in treating conditions associated with excess estrogen or irregular menstrual cycles.

Pharmacokinetics

Hydroxyprogesterone is well absorbed following intramuscular administration. It is metabolized predominantly in the liver, where it undergoes extensive first-pass metabolism. The half-life varies depending on the route of administration, but it is generally around 24 hours. The drug is excreted primarily in the urine as metabolites, with minimal unchanged drug eliminated.

Contra-indications

• Known or suspected pregnancy
• Active or past venous thromboembolism
• Severe liver disease
• Hormone-dependent tumors
• Undiagnosed vaginal bleeding

Adverse effects

• Nausea
• Headache
• Breast tenderness
• Mood changes
• Weight gain
• Edema
• Thromboembolic disorders

Interactions

• Anticonvulsants may decrease effectiveness of hydroxyprogesterone
• Rifampicin may decrease hydroxyprogesterone levels
• St. John's Wort may reduce the effectiveness of hydroxyprogesterone

Precautions

• Monitor for signs of thrombosis
• Use with caution in patients with a history of depression
• Regular gynecological examinations are recommended
• Assess risk factors for cardiovascular disease

Pregnancy

Hydroxyprogesterone is contraindicated during pregnancy due to potential risks to the fetus.

Breast-feeding

Hydroxyprogesterone is excreted in breast milk; caution is advised when administered to nursing mothers.

Storage

Store in a cool, dry place, away from direct light. Keep out of reach of children.

Formulations

• Injectable solution
• Capsules

Mechanism of action

ADMIN OF ESTROGEN & PROGESTIN, AS CONTAINED IN COMBINATION OR SEQUENTIAL PREPN, COULD INTERFERE WITH FERTILITY IN ANY ONE OF SEVERAL WAYS. HOWEVER, IT IS CLEAR THAT, AS CURRENTLY USED, MIXTURE INHIBITS OVULATION. ...CONTINUED ACTION OF PROGESTERONE SERVES TO INHIBIT RELEASE OF LH. /PROGESTINS/ IT ACTS AS ANTIGONADOTROPHIC AGENT ON ANTERIOR PITUITARY INHIBITING FSH RELEASE &, THUS, FOLLICULAR GROWTH, ESTROGEN PRODUCTION, & ESTRUS. IT ALSO INHIBITS LH RELEASE, THUS PREVENTING OVULATION, CORPORA LUTEA FORMATION, & FURTHER PROGESTERONE SECRETION. BY INHIBITING LH...HOLDS PROGESTERONE LEVELS IN CHECK.